Abstract
Combining molecular and anatomical imaging, positron emission tomography/magnetic resonance imaging (PET/MRI) can be used for diagnosis, staging, restaging and evaluation of treatment response in urologic oncology. PET/MRI is superior to PET/computed tomography (CT) in the characterization of incidentally detected adrenal and renal lesions. However, the role of PET/MRI in the management of adrenocortical cancer, pheochromocytoma, renal cell carcinoma and urothelial cancers has not yet been definitively established. Although its routine use in renal and bladder cancer staging is controversial, PET/MRI is an effective method for detecting metastases of these cancers and evaluating the local spread of bladder cancer. Gallium-68 prostate-specific membrane antigen (PSMA) PET/MRI is a hybrid imaging modality that allows detailed and reliable evaluation of prostate cancer. It can also be used to detect prostate cancer in patients with high prostate-specific antigen levels. The integration of PET and MRI technologies allows for more precise and reliable detection of tumor localization. This can make prostate biopsies safer and more diagnostic. PSMA PET/MRI is superior to PSMA PET/CT for local staging of prostate cancer and detection of recurrence after treatment. PET/MRI has a lower radiation dose compared to conventional PET/CT scans, making it a safer option for follow-up imaging in oncologic patients.
Keywords: FDG, PSMA, PET/MRI, adrenal gland, kidney, bladder, prostate
References
Ashraf MA, Goyal A. Fludeoxyglucose (18F). 2023 Aug 28. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan-.
Broski SM, Goenka AH, Kemp BJ, Johnson GB. Clinical PET/MRI: 2018 update.AJR Am J Roentgenol. 2018; 211: 295-313.
Boland GW, Dwamena BA, Jagtiani Sangwaiya M, Goehler AG, Blake MA, et al. Characterization of adrenal masses by using FDG PET: a systematic review and meta-analysis of diagnostic test performance.Radiology. 2011; 259: 117-26.
Song JH, Chaudhry FS, Mayo-Smith WW. The incidental adrenal mass on CT: prevalence of adrenal disease in 1,049 consecutive adrenal masses in patients with no known malignancy.AJR Am J Roentgenol. 2008; 190: 1163-8.
Ansquer C, Scigliano S, Mirallié E, Taïeb D, Brunaud L, Sebag F, et al. 18F-FDG PET/CT in the characterization and surgical decision concerning adrenal masses: a prospective multicentre evaluation.Eur J Nucl Med Mol Imaging. 2010; 37: 1669-78.
Dong A, Cui Y, Wang Y, Zuo C, Bai Y. (18)F-FDG PET/CT of adrenal lesions.AJR Am J Roentgenol. 2014; 203: 245-52.
Boland GW, Blake MA, Holalkere NS, Hahn PF. PET/CT for the characterization of adrenal masses in patients with cancer: qualitative versus quantitative accuracy in 150 consecutive patients.AJR Am J Roentgenol. 2009; 192: 956-62.
Metser U, Miller E, Lerman H, Lievshitz G, Avital S, Even-Sapir E. 18F-FDG PET/CT in the evaluation of adrenal masses.J Nucl Med. 2006; 47: 32-7.
Shimizu A, Oriuchi N, Tsushima Y, Higuchi T, Aoki J, Endo K. High [18F] 2-fluoro-2-deoxy-D-glucose (FDG) uptake of adrenocortical adenoma showing subclinical Cushing’s syndrome.Ann Nucl Med. 2003; 17: 403-6.
Adam SZ, Nikolaidis P, Horowitz JM, Gabriel H, Hammond NA, Patel T, et al. Chemical shift MR imaging of the adrenal gland: principles, pitfalls, and applications.Radiographics. 2016; 36: 414-32.
Schaarschmidt BM, Grueneisen J, Heusch P, Gomez B, Umutlu L, Ruhlmann V, et al. Does 18F-FDG PET/MRI reduce the number of indeterminate abdominal incidentalomas compared with 18F-FDG PET/CT?Nucl Med Commun. 2015; 36: 588-95.
Rao P, Kenney PJ, Wagner BJ, Davidson AJ. Imaging and pathologic features of myelolipoma.Radiographics. 1997; 17: 1373-85.
Koopmans KP, Jager PL, Kema IP, Kerstens MN, Albers F, Dullaart RP. 111In-octreotide is superior to 123I-metaiodobenzylguanidine for scintigraphic detection of head and neck paragangliomas.J Nucl Med. 2008; 49: 1232-7.
Tan TH, Hussein Z, Saad FF, Shuaib IL. Diagnostic performance of (68)Ga-DOTATATE PET/CT, (18)F-FDG PET/CT and (131)I-MIBG scintigraphy in mapping metastatic pheochromocytoma and paraganglioma.Nucl Med Mol Imaging. 2015; 49: 143-51. Erratum in: Nucl Med Mol Imaging. 2015; 49: 152.
Xu S, Pan Y, Zhou J, Ju H, Zhang Y. Integrated PET/MRI with 68Ga-DOTATATE and 18F-FDG in pheochromocytomas and paragangliomas: an initial study.Clin Nucl Med. 2022; 47: 299-304.
Chang CA, Pattison DA, Tothill RW, Kong G, Akhurst TJ, Hicks RJ, et al. (68)Ga-DOTATATE and (18)F-FDG PET/CT in paraganglioma and pheochromocytoma: utility, patterns and heterogeneity.Cancer Imaging. 2016; 16: 22.
Leboulleux S, Dromain C, Bonniaud G, Aupérin A, Caillou B, Lumbroso J, et al. Diagnostic and prognostic value of 18-fluorodeoxyglucose positron emission tomography in adrenocortical carcinoma: a prospective comparison with computed tomography.J Clin Endocrinol Metab. 2006; 91: 920-5.
Zhou L, Peng W, Wang C, Liu X, Shen Y, Zhou K. Primary adrenal lymphoma: radiological; pathological, clinical correlation.Eur J Radiol. 2012; 81: 401-5.
Evangelista L, Crimì F, Visentin A, Voltan G, Trentin L, Lacognata C, et al. [18F]FDG PET/CT and PET/MR in patients with adrenal lymphoma: a systematic review of literature and a collection of cases.Curr Oncol. 2022; 29: 7887-99.
Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.CA Cancer J Clin. 2021; 71: 209-49.
Data visualization tools for exploring the global cancer burden in 2022.
Le O, Roy A, Silverman PM, Kundra V. Common and uncommon adult unilateral renal masses other than renal cell carcinoma.Cancer Imaging. 2012; 12: 194-204.
Krajewski KM, Pedrosa I. Imaging advances in the management of kidney cancer.J Clin Oncol. 2018; 36: JCO2018791236.
Kochhar R, Brown RK, Wong CO, Dunnick NR, Frey KA, Manoharan P. Role of FDG PET/CT in imaging of renal lesions.J Med Imaging Radiat Oncol. 2010; 54: 347-57.
Nakajima R, Nozaki S, Kondo T, Nagashima Y, Abe K, Sakai S. Evaluation of renal cell carcinoma histological subtype and fuhrman grade usingF-fluorodeoxyglucose-positron emission tomography/computed tomography. Eur Radiol. 2017; 27: 4866-73.
Zukotynski K, Lewis A, O’Regan K, Jacene H, Sakellis C, Krajewski K, et al. PET/CT and renal pathology: a blind spot for radiologists? Part 1, primary pathology.AJR Am J Roentgenol. 2012; 199: W163-7.
Kitajima K, Yamamoto S, Fukushima K, Minamimoto R, Kamai T, Jadvar H. Update on advances in molecular PET in urological oncology.Jpn J Radiol. 2016; 34: 470-85.
Kang DE, White RL Jr, Zuger JH, Sasser HC, Teigland CM. Clinical use of fluorodeoxyglucose F 18 positron emission tomography for detection of renal cell carcinoma.J Urol. 2004; 171: 1806-9.
Yin Q, Xu H, Zhong Y, Ni J, Hu S. Diagnostic performance of MRI, SPECT, and PET in detecting renal cell carcinoma: a systematic review and meta-analysis.BMC Cancer. 2022; 22: 163.
Lakhani A, Khan SR, Bharwani N, Stewart V, Rockall AG, Khan S, et al. FDG PET/CT pitfalls in gynecologic and genitourinary oncologic imaging.Radiographics. 2017; 37: 577-94.
Liu Y. The Place of FDG PET/CT in renal cell carcinoma: value and limitations.Front Oncol. 2016; 6: 201.
Ma H, Shen G, Liu B, Yang Y, Ren P, Kuang A. Diagnostic performance of 18F-FDG PET or PET/CT in restaging renal cell carcinoma: a systematic review and meta-analysis.Nucl Med Commun. 2017; 38: 156-63.
Takahashi M, Kume H, Koyama K, Nakagawa T, Fujimura T, Morikawa T, et al. Preoperative evaluation of renal cell carcinoma by using 18F-FDG PET/CT.Clin Nucl Med. 2015; 40: 936-40.
Lee H, Hwang KH, Kim SG, Koh G, Kim JH. Can Initial (18)F-FDG PET-CT imaging give information on metastasis in patients with primary renal cell carcinoma?Nucl Med Mol Imaging. 2014; 48: 144-52.
Quencer KB, Friedman T, Sheth R, Oklu R. Tumor thrombus: incidence, imaging, prognosis and treatment.Cardiovasc Diagn Ther. 2017; 7 (Suppl 3): S165-S77.
Ferda J, Ferdova E, Hora M, Hes O, Finek J, Topolcan O, et al. 18F-FDG-PET/CT in potentially advanced renal cell carcinoma: a role in treatment decisions and prognosis estimation.Anticancer Res. 2013; 33: 2665-72.
Sharma P, Kumar R, Jeph S, Karunanithi S, Naswa N, Gupta A, Malhotra A. 18F-FDG PET-CT in the diagnosis of tumor thrombus: can it be differentiated from benign thrombus?Nucl Med Commun. 2011; 32: 782-8.
Chen JL, Appelbaum DE, Kocherginsky M, Cowey CL, Rathmell WK, McDermott DF, et al. FDG-PET as a predictive biomarker for therapy with everolimus in metastatic renal cell cancer.Cancer Med. 2013; 2: 545-52.
Caldarella C, Muoio B, Isgrò MA, Porfiri E, Treglia G, Giovanella L. The role of fluorine-18-fluorodeoxyglucose positron emission tomography in evaluating the response to tyrosine-kinase inhibitors in patients with metastatic primary renal cell carcinoma.Radiol Oncol. 2014; 48: 219-27.
Lai AL, Law YM. VI-RADS in bladder cancer: overview, pearls and pitfalls.Eur J Radiol. 2023; 160: 110666.
Spiess PE, Agarwal N, Bangs R, Boorjian SA, Buyyounouski MK, Clark PE, et al. Bladder cancer, version 5.2017, NCCN Clinical Practice Guidelines in Oncology.J Natl Compr Canc Netw. 2017; 15: 1240-67.
Civelek AC, Niglio SA, Malayeri AA, Lin J, Gurram S, Chalfin HJ, et al. Clinical value ofFDG PET/MRI in muscle-invasive, locally advanced, and metastatic bladder cancer. Urol Oncol. 2021; 39: 787.e17-787.e21.
Rosenkrantz AB, Friedman KP, Ponzo F, Raad RA, Jackson K, Huang WC, et al. Prospective pilot study to evaluate the incremental value of PET information in patients with bladder cancer undergoing 18F-FDG simultaneous PET/MRI.Clin Nucl Med. 2017; 42: e8-e15.
Lu YY, Chen JH, Liang JA, Wang HY, Lin CC, Lin WY, et al. Clinical value of FDG PET or PET/CT in urinary bladder cancer: a systemic review and meta-analysis.Eur J Radiol. 2012; 81: 2411-6.
Soubra A, Hayward D, Dahm P, Goldfarb R, Froehlich J, Jha G, et al. The diagnostic accuracy of 18F-fluorodeoxyglucose positron emission tomography and computed tomography in staging bladder cancer: a single-institution study and a systematic review with meta-analysis.World J Urol. 2016; 34: 1229-37.
Giannatempo P, Alessi A, Miceli R, Raggi D, Farè E, Nicolai N, et al. Interim fluorine-18 fluorodeoxyglucose positron emission tomography for early metabolic assessment of therapeutic response to chemotherapy for metastatic transitional cell carcinoma.Clin Genitourin Cancer. 2014; 12: 433-9.
Mertens LS, Fioole-Bruining A, van Rhijn BW, Kerst JM, Bergman AM, Vogel WV, et al. FDG-positron emission tomography/computerized tomography for monitoring the response of pelvic lymph node metastasis to neoadjuvant chemotherapy for bladder cancer.J Urol. 2013; 189: 1687-91.
Salminen A, Jambor I, Merisaari H, Ettala O, Virtanen J, Koskinen I, et al.C-acetate PET/MRI in bladder cancer staging and treatment response evaluation to neoadjuvant chemotherapy: a prospective multicenter study (ACEBIB trial). Cancer Imaging. 2018; 18: 25.
Cereser L, Evangelista L, Giannarini G, Girometti R. Prostate MRI and PSMA-PET in the primary diagnosis of prostate cancer.Diagnostics (Basel). 2023; 13: 2697.
Hope TA, Afshar-Oromieh A, Eiber M, Emmett L, Fendler WP, Lawhn-Heath C, et al. Imaging prostate cancer with prostate-specific membrane antigen PET/CT and PET/MRI: current and future applications.AJR Am J Roentgenol. 2018; 211: 286-94.
Hofman MS, Iravani A. Gallium-68 prostate-specific membrane antigen PET imaging.PET Clin. 2017; 12: 219-34.
Liu FY, Sheng TW, Tseng JR, Yu KJ, Tsui KH, Pang ST, et al. Prostate-specific membrane antigen (PSMA) fusion imaging in prostate cancer: PET-CTvs PET-MRI. Br J Radiol. 2022; 95: 20210728.
Huang R, Li Y, Wu H, Liu B, Zhang X, Zhang Z.Ga-PSMA-11 PET/CT versus Ga-PSMA-11 PET/MRI for the detection of biochemically recurrent prostate cancer: a systematic review and meta-analysis. Front Oncol. 2023; 13: 1216894.
Hicks RM, Simko JP, Westphalen AC, Nguyen HG, Greene KL, Zhang L, et al. Diagnostic accuracy ofGa-PSMA-11 PET/MRI compared with multiparametric MRI in the detection of prostate cancer. Radiology. 2018; 289: 730-7.
Margel D, Bernstine H, Groshar D, Ber Y, Nezrit O, Segal N, et al. Diagnostic performance ofGa prostate-specific membrane antigen PET/MRI compared with multiparametric MRI for detecting clinically significant prostate cancer. Radiology. 2021; 301: 379-86.
Ferraro DA, Becker AS, Kranzbühler B, Mebert I, Baltensperger A, Zeimpekis KG, et al. Diagnostic performance ofGa-PSMA-11 PET/MRI-guided biopsy in patients with suspected prostate cancer: a prospective single-center study. Eur J Nucl Med Mol Imaging. 2021; 48: 3315-24.
Hope TA, Goodman JZ, Allen IE, Calais J, Fendler WP, Carroll PR. Metaanalysis ofGa-PSMA-11 PET accuracy for the detection of prostate cancer validated by histopathology. J Nucl Med. 2019; 60: 786-93.
Evangelista L, Zattoni F, Cassarino G, Artioli P, Cecchin D, Dal Moro F, et al. PET/MRI in prostate cancer: a systematic review and meta-analysis.Eur J Nucl Med Mol Imaging. 2021; 48: 859-73.
Park SY, Zacharias C, Harrison C, Fan RE, Kunder C, Hatami N, et al. Gallium 68 PSMA-11 PET/MR Imaging in Patients with Intermediate- or high-risk prostate cancer.Radiology. 2018; 288: 495-505.
Rüschoff JH, Ferraro DA, Muehlematter UJ, Laudicella R, Hermanns T, Rodewald AK, et al. What’s behindGa-PSMA-11 uptake in primary prostate cancer PET? Investigation of histopathological parameters and immunohistochemical PSMA expression patterns. Eur J Nucl Med Mol Imaging. 2021; 48: 4042-53.
Muehlematter UJ, Burger IA, Becker AS, Schawkat K, Hötker AM, Reiner CS, et al. Diagnostic accuracy of multiparametric MRI versusGa-PSMA-11 PET/MRI for extracapsular extension and seminal vesicle invasion in patients with prostate cancer. Radiology. 2019; 293: 350-8.
Datta K, Muders M, Zhang H, Tindall DJ. Mechanism of lymph node metastasis in prostate cancer.Future Oncol. 2010; 6: 823-36.
Ghafoor S, Burger IA, Vargas AH. Multimodality imaging of prostate cancer.J Nucl Med. 2019; 60: 1350-8.
Herlemann A, Wenter V, Kretschmer A, Thierfelder KM, Bartenstein P, Faber C, et al.Ga-PSMA positron emission tomography/computed tomography provides accurate staging of lymph node regions prior to lymph node dissection in patients with prostate cancer. Eur Urol. 2016; 70: 553-7.
Hofman MS, Lawrentschuk N, Francis RJ, Tang C, Vela I, Thomas P, et al. Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study.Lancet. 2020; 395: 1208-16.
Quiroz-Munoz M, Izadmehr S, Arumugam D, Wong B, Kirschenbaum A, Levine AC. Mechanisms of osteoblastic bone metastasis in prostate cancer: role of prostatic acid phosphatase.J Endocr Soc. 2019; 3: 655-64.
Donswijk ML, van Leeuwen PJ, Vegt E, Cheung Z, Heijmink SWTPJ, van der Poel HG, et al. Clinical impact of PSMA PET/CT in primary prostate cancer compared to conventional nodal and distant staging: a retrospective single center study.BMC Cancer. 2020; 20: 723.
Zhao Y, Morka N, Simpson BSS, Freeman A, Kirkham A, Kelly D, et al. Prostate-specific membrane antigen positron emission tomography compared to multiparametric MRI for prostate cancer diagnosis: a protocol for a systematic review and meta-analysis.BMJ Open. 2021; 11: e052277.
Pasoglou V, Michoux N, Peeters F, Larbi A, Tombal B, Selleslagh T, et al. Whole-body 3D T1-weighted MR imaging in patients with prostate cancer: feasibility and evaluation in screening for metastatic disease.Radiology. 2015; 275: 155-66.
Catalano OA, Nicolai E, Rosen BR, Luongo A, Catalano M, Iannace C, et al. Comparison of CE-FDG-PET/CT with CE-FDG-PET/MR in the evaluation of osseous metastases in breast cancer patients.Br J Cancer. 2015; 112: 1452-60.
Grubmüller B, Baltzer P, Hartenbach S, D’Andrea D, Helbich TH, Haug AR, et al. PSMA ligand PET/MRI for primary prostate cancer: staging performance and clinical impact.Clin Cancer Res. 2018; 24: 6300-7.
Ferraro DA, Muehlematter UJ, Garcia Schüler HI, Rupp NJ, Huellner M, Messerli M, et al.Ga-PSMA-11 PET has the potential to improve patient selection for extended pelvic lymph node dissection in intermediate to high-risk prostate cancer. Eur J Nucl Med Mol Imaging. 2020; 47: 147-59.
McCormick BZ, Mahmoud AM, Williams SB, Davis JW. Biochemical recurrence after radical prostatectomy: current status of its use as a treatment endpoint and early management strategies.Indian J Urol. 2019; 35: 6-17.
Patel P, Mathew MS, Trilisky I, Oto A. Multiparametric MR imaging of the prostate after treatment of prostate cancer.Radiographics. 2018; 38: 437-49.
Gaur S, Turkbey B. Prostate MR imaging for posttreatment evaluation and recurrence.Radiol Clin North Am. 2018; 56: 263-75.
Notley M, et al. BJR 2015, Roy C, et al. AJR 2013, Sciarra et al. Eur Urol 2008.
Fendler WP, Calais J, Eiber M, Flavell RR, Mishoe A, Feng FY, et al. Assessment of 68Ga-PSMA-11 PET accuracy in localizing recurrent prostate cancer: a prospective single-arm clinical trial.JAMA Oncol. 2019; 5: 856-63.
Kranzbühler B, Müller J, Becker AS, Garcia Schüler HI, Muehlematter U, Fankhauser CD, et al. Detection rate and localization of prostate cancer recurrence usingGa-PSMA-11 PET/MRI in patients with low PSA values ≤ 0.5 ng/mL. J Nucl Med. 2020; 61: 194-201.
Guberina N, Hetkamp P, Ruebben H, Fendler W, Grueneisen J, Suntharalingam S, et al. Whole-body integrated [Ga]PSMA-11-PET/MR imaging in patients with recurrent prostate cancer: comparison with whole-body PET/CT as the standard of reference. Mol Imaging Biol. 2020; 22: 788-96.
Jentjens S, Mai C, Ahmadi Bidakhvidi N, De Coster L, Mertens N, Koole M, et al. Prospective comparison of simultaneous [Ga]Ga-PSMA-11 PET/MR versus PET/CT in patients with biochemically recurrent prostate cancer. Eur Radiol. 2022; 32: 901-11.
